Recent developments for Day One Biopharmaceuticals include a significant acquisition agreement with Servier Pharmaceuticals LLC valued at $2.5 billion, strong sales growth of its lead product OJEMDA™, and reaffirmation of 2026 revenue guidance. The company reported narrowing net losses in Q4 2025 and ongoing clinical trial progress.

• On March 6, 2026, Day One Biopharmaceuticals entered into a merger agreement to be acquired by Servier Pharmaceuticals LLC for $2.5 billion, with shares surging following the announcement [N5][N3][N2].
• The tender offer price is $21.50 per share in cash, subject to conditions including majority shareholder tender and regulatory approvals [N5][N2].
• Day One reported an 82% increase in OJEMDA sales in Q4 2025 and reaffirmed its 2026 net product revenue guidance [N6][N7].
• The company continues to advance clinical trials including the pivotal Phase 3 FIREFLY-2 trial and Phase 1a trial for DAY301, with data milestones anticipated in 2026 [N8].
• The acquisition offer and related tender offer expired on January 5, 2026, with over 60% of shares tendered by that date [S1].
• The company maintains strong liquidity with cash and short-term investments totaling approximately $441 million as of December 31, 2025 [S1].
• Day One has contingent value rights agreements related to milestone payments for its Emi-Le program, with payments contingent on regulatory and sales milestones through 2037 [S1].
• The company reaffirmed its FY26 guidance despite a net loss narrowing in Q4 2025, reflecting ongoing investment in growth and development [N6].
• The board of directors includes experienced biopharmaceutical industry leaders providing governance and strategic oversight [S1].
• Day One's corporate presentations and financial disclosures have been updated and filed with the SEC, reflecting transparency and compliance [S1].

Day One's lead product OJEMDA™ has demonstrated strong sales growth, with an 82% increase in Q4 2025, indicating market acceptance in its niche pediatric oncology segment. The company's robust liquidity position supports ongoing clinical development and commercialization efforts. The pending acquisition by Servier Pharmaceuticals LLC at a $2.5 billion valuation reflects strategic interest and potential for integration into a larger pharmaceutical platform. The pipeline programs, including the FIREFLY-2 Phase 3 trial and the DAY301 antibody drug conjugate, offer additional avenues for growth and value creation through clinical milestones and potential regulatory approvals.

Day One reported a significant net loss of approximately $107.3 billion for 2025, reflecting high operating costs and investment in clinical development. The biopharmaceutical sector's inherent risks include clinical trial failures, regulatory delays, and competitive pressures that could impact product commercialization and revenue growth. The acquisition is subject to shareholder tender and regulatory approvals, with risks related to integration and potential disruption to ongoing operations. Contingent milestone payments tied to the Emi-Le program may not be realized if development or sales targets are not met, adding uncertainty to future cash flows.

Day One Biopharmaceuticals' moat is primarily based on its specialized focus on pediatric oncology, particularly with its lead product OJEMDA™ (tovorafenib) targeting BRAF-altered pediatric low-grade glioma. The exclusive licensing agreement with Ipsen for commercialization outside the U.S. extends its geographic reach. The company's clinical pipeline, including novel antibody drug conjugates and targeted therapies, supports its competitive positioning. However, the biopharmaceutical industry is highly competitive and subject to regulatory and clinical development risks, which may impact the sustainability of its competitive advantages.

• Acquisition Completion Risks: The merger agreement with Servier Pharmaceuticals LLC is subject to conditions including majority shareholder tender, regulatory approvals, and absence of competing offers. Failure to meet these conditions could delay or prevent the acquisition.
• Clinical Development Risks: Ongoing clinical trials such as FIREFLY-2 and Phase 1a for DAY301 carry risks of delays, unfavorable results, or failure to achieve regulatory approvals, which could impact future product launches and revenue.
• Financial Performance Risks: The company reported a large net loss in 2025, indicating significant expenses relative to revenue. Continued losses could affect liquidity and operational flexibility.
• Market and Competitive Risks: Day One operates in a competitive biopharmaceutical environment with potential pricing pressures, regulatory changes, and competition from other therapies that could affect market share and profitability.
• Integration Risks: Post-acquisition integration challenges may disrupt business operations, employee retention, and relationships with suppliers and customers.

• Day One Biopharmaceuticals, Inc. is a Delaware corporation engaged in biopharmaceutical development.
• The company is listed on the Nasdaq Global Select Market under the ticker DAWN.
• As of December 31, 2025, the company reported cash and cash equivalents of $197.1 million and short-term investments of $244.0 million, totaling $441.1 million in liquid assets.
• Current assets as of December 31, 2025, were $485.1 million, with current liabilities of $60.5 million, resulting in a current ratio of 8.02 and a cash ratio of 7.29, indicating strong liquidity.
• For the fiscal year ended December 31, 2025, Day One reported revenues of $158.2 million.
• The company reported a net loss of approximately $107.3 billion for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$1.04 per share.
• Day One's product portfolio includes OJEMDA™ (tovorafenib), a treatment for pediatric low-grade glioma, with Ipsen holding exclusive commercialization rights outside the United States.
• The company has ongoing clinical trials including the pivotal Phase 3 FIREFLY-2 trial for tovorafenib and Phase 1a trial for DAY301, a PTK7-targeted antibody drug conjugate, with data milestones anticipated in 2026.
• Day One entered into an Agreement and Plan of Merger on March 6, 2026, with Servier Pharmaceuticals LLC, under which Servier will acquire Day One for $21.50 per share in cash, subject to conditions including majority tender of shares.
• The acquisition offer values the company at approximately $2.5 billion.
• The tender offer was scheduled to expire on January 5, 2026, with over 60% of shares tendered by that date.
• The company reaffirmed its 2026 net product revenue guidance and reported an 82% increase in OJEMDA sales in Q4 2025.
• Day One has a contingent value rights (CVR) agreement related to milestone payments for its Emi-Le program, with payments contingent on regulatory and sales milestones through 2037.
• The company has a board of directors with members experienced in biopharmaceutical leadership and corporate governance.
• Day One's financial disclosures and corporate presentations have been updated and filed with the SEC, including a 10-K/A amendment filed on April 17, 2026.
• The company operates in a competitive and rapidly changing biopharmaceutical environment with risks related to clinical development, regulatory approvals, and integration post-acquisition.